The newest GLP-1 drugs in 2026 are retatrutide (an investigational triple GLP-1/GIP/glucagon agonist still in Phase 3 trials), orforglipron (an oral small-molecule pill that the FDA approved in April 2026 for chronic weight management), and CagriSema (a GLP-1 plus amylin combination that Novo Nordisk has filed for approval but the FDA has not yet cleared)
Fact: The body has a limit on how much it can process at once
My medication comes properly refrigerated and arrives exactly when promised, and when I decided to stay at a lower dose that was doing the job, the team respected that decision rather than pressuring me to go higher
Months 3 to 6: The full benefits become evident
2010;59(6):1386-96 Vasamsetti SB, Karnewar S, Kanugula AK, et al
Sun Exposure: The product reduces any need for prolonged sunbathing, but a small amount of sunlight (1015 minutes) helps activate melanin production for better results